secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001193125-26-031792
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema CFO/COO Kovacs departs Jan 30; CEO Bohen interim principal financial officer
--------------------------------------------------------------------------------

- Shane Kovacs, COO and CFO, leaves Jan 30, 2026; not due to disagreement with company on financial operations.
- Kovacs receives $621,283 lump sum: $562,640 salary, $23,443 prorated 2026 bonus, $35,200 COBRA.
- Outstanding equity awards continue vesting while he consults through Aug 1, 2026.
- CEO Sean Bohen, M.D., Ph.D., assumes interim principal financial officer role; search for permanent CFO launched.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526031792/0001193125-26-031792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526031792/d126625d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-031792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer